Cellectis
Develops allogeneic, or 'off-the-shelf', CAR T-cell immunotherapies for cancer.
ALCLS | PA
Overview
Corporate Details
- ISIN(s):
- FR0010425595 (+2 more)
- LEI:
- 5493000KKX5VQ37Q2W83
- Country:
- France
- Address:
- 8 RUE DE LA CROIX JARRY, 75013 PARIS
- Website:
- https://cellectis.com/en
- Sector:
- Manufacturing
Description
Cellectis is a clinical-stage biopharmaceutical company specializing in the development of immunotherapies to treat cancer. The company leverages its proprietary gene-editing platform, TALEN®, to engineer Chimeric Antigen Receptor (CAR) T-cells. Its primary focus is on creating allogeneic, or 'off-the-shelf', CAR T-cell product candidates. These therapies are derived from T-cells from healthy donors and are designed to be broadly available for a large number of patients, in contrast to autologous therapies custom-made for each individual. The TALEN® technology is used to address key challenges in allogeneic cell therapy, including preventing Graft-versus-Host Disease and mitigating rejection by the patient's immune system.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2022-10-27 22:37 |
Cellectis organise une conférence téléphonique pour présenter ses résultats fin…
|
French | 71.4 KB | ||
| 2022-10-27 22:37 |
Cellectis to Report Third Quarter 2022 Financial Results
|
English | 56.3 KB | ||
| 2022-10-11 22:30 |
Cellectis présente des données sur deux programmes précliniques de thérapies gé…
|
French | 75.3 KB | ||
| 2022-10-11 22:30 |
Cellectis Presents Data on Two TALEN®-based Gene Therapy Preclinical Programs f…
|
English | 109.8 KB | ||
| 2022-10-10 22:30 |
Information mensuelle relative au nombre total des droits de vote et d’actions …
|
French | 84.8 KB | ||
| 2022-10-10 22:30 |
Monthly information on share capital and company voting rights
|
English | 77.6 KB | ||
| 2022-10-05 22:30 |
Cellectis présentera des données précliniques sur des cellules “smart” CAR T éd…
|
French | 69.2 KB | ||
| 2022-10-05 22:30 |
Cellectis to Present Pre-Clinical Data on TALEN®-edited Smart CAR T-cells Suppo…
|
English | 76.5 KB | ||
| 2022-09-28 22:23 |
Cellectis Appoints Mark Frattini, M.D., Ph.D. as Chief Medical Officer
|
English | 80.9 KB | ||
| 2022-09-28 22:21 |
Cellectis nomme Mark Frattini, M.D., Ph.D., en tant que directeur médical
|
French | 79.9 KB | ||
| 2022-09-19 22:30 |
Information mensuelle relative au nombre total des droits de vote et d’actions …
|
French | 84.8 KB | ||
| 2022-09-19 22:30 |
Monthly information on share capital and company voting rights
|
English | 77.5 KB | ||
| 2022-09-01 22:56 |
Cellectis annonce sa participation à quatre conférences investisseurs en septem…
|
French | 96.3 KB | ||
| 2022-09-01 22:44 |
Cellectis Announces Participation in Four Upcoming Investor Conferences in Sept…
|
English | 91.5 KB | ||
| 2022-08-22 22:30 |
Monthly information on share capital and company voting rights
|
English | 77.6 KB |
Automate Your Workflow. Get a real-time feed of all Cellectis filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Cellectis
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Cellectis via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
